Opportunities and challenges for use of minipigs in nonclinical pharmaceutical development: Results of a follow-up IQ DruSafe survey
David O. Clarke(Eli Lilly (United States)), Thierry Flandre(Novartis (Switzerland)), Michael W. Leach(Pfizer (United States)), Smita Salian‐Mehta(Diabetes Australia), Michael J. Graziano(The Bristol-Myers Squibb Children's Hospital), Binod Jacob(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kaushik Datta(Bristol-Myers Squibb (Germany)), Béatrice Gauthier(Sanofi (France)), Kevin J. French(GlaxoSmithKline (United States)), Joanna Harding(AstraZeneca (United Kingdom)), Drew Olaharski(Relay Therapeutics (United States)), Devon Strein(Boehringer Ingelheim (United States)), R. D. Lange(AbbVie (United States)), Kenneth Hershman(Novartis (Switzerland)), Shaofei Ji(Johnson & Johnson (United States)), Bianca Feyen, Brian Sayers(Incyte (United States)), Susanne Mohr(Roche (Switzerland))
Cited by 4
Related Papers
Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2
|Journal of Pharmacology and Experimental Therapeutics|2010|313
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
|Regulatory Toxicology and Pharmacology|2022|32
Survey results on the use of the tissue cross-reactivity immunohistochemistry assay
|Regulatory Toxicology and Pharmacology|2010|24
Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement
|Journal of Biological Chemistry|2015|17
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
|Regulatory Toxicology and Pharmacology|2023|15